Advertisement
Dear Shareholder,
The previous year has been a noteworthy one for ImmuneRegen BioSciences.Our scientific and business activities have accelerated, and the company hasrecently announced several noteworthy achievements and events such asacquisition of study results, formation of collaborative and co-developmentrelationships as well as presentations at conferences and to the FDA and NIH.The response by these agencies of the Department of Health and Human Servicesremains quite positive as we continue to deliver additional data in multipleareas of both scientific and product development interest and having potentialcommercial appeal.
Advertisement
Current research programs include microbiological infection such asanthrax bacillus, and influenza (including avian influenza vaccine adjuvancy),in addition to radiation exposure (to both lethal and sub-lethal/therapeuticdoses). Results of our influenza studies indicate that Viprovex(R) lowersviral load 90-99% in nose and lungs of treated animals, as well as lowers themagnitude of the virus-induced decreases in body weight and temperature. Thesestudies also indicate that Viprovex decreases the inflammatory reaction in thelungs of infected animals, even in the presence of Roche's influenza treatmentand preventative, Tamiflu(R). The company is continuing Tamiflu/Viprovexstudies and they are underway. Our radiation exposure studies, originally forbiodefense applications and terrorist attacks have been extended to includepotential cancer therapy applications. The radiation results have indicatedrecovery of circulating white blood cells, and potential stimulatory effectson stem cell proliferation and/or maturation. Wound healing is also a marketin which we anticipate forthcoming success. Results from recently concludedstudies indicate positive effects in the area and we expect our drug candidateto continue to demonstrate positive results as a potential growth factor. Wealso believe that our recently announced relationships with companies such asUluru Inc. will expedite our efforts in wound healing.
In the opinion of management the current stock valuation does not reflectthe newly acquired data and relationships. We continue to successfullydevelop business relationships with potential partners and advance our productdevelopment activities in multiple, sizeable markets. For example, thebiodefense and pandemic influenza market has been estimated at a combinedtotal of $6.1 billion with seasonal influenza opportunities, as a therapeuticor adjuvant to vaccination representing $2 billion total market revenues in2006. Cancer therapies for mitigating side effects to toxic therapy and/orpotentially playing a therapeutic role in the stem cell area of medicaltreatments has a combined commercial market worldwide estimated at $16.1billion in revenue. Additionally, we hope to achieve continual successfulresults in the wound healing studies that we have currently partnered withUluru, Inc. We are collectively working toward adding additionalpharmaceutical company partnerships so we can develop effective wound healingtreatments that can theoretically address a broad range of applications:diabetic ulcers, trauma, surgical wounds, day to day cuts and scrapes. For2006, the global wound care market represented $7 billion in sales. A recentrepor
